# Prognosis of synchronous colorectal carcinoma compared to solitary colorectal carcinoma: a matched pair analysis

Wanbin He<sup>a,\*</sup>, Chengjun Zheng<sup>a,\*</sup>, Yonghong Wang<sup>a</sup>, Jie Dan<sup>a</sup>, Mingjie Zhu<sup>a</sup>, Mingtian Wei<sup>b</sup>, Jian Wang<sup>a</sup> and Ziqiang Wang<sup>b</sup>

**Background** Synchronous colorectal carcinoma (CRC) is a specific and rare type of colorectal malignancy. The data on the impact of synchronous CRC are controversial. This study aimed to compare the characteristics and prognosis between synchronous CRC and solitary CRC.

**Patients and methods** 252 patients who underwent surgery between October 2009 and June 2013 with synchronous CRC (n = 126) or solitary CRC (n = 126) were included. The patients were matched according to age, sex, American Society of Anesthesiologists score, BMI, cancer grade, tumor location, and tumor stage. The short-term outcomes included the length of hospital stay, complications, and 30-day mortality. Long-term endpoints were overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS).

**Results** The median follow-up duration for all patients were 42.5 months. The incidence of synchronous CRC was high than in older and male patients as well as in mucinous adenocarcinoma containing signet-ring cell carcinoma, tumor deposit, and polypus. The length of hospital stay after surgery was longer for synchronous CRC than solitary CRC (median: 10 vs. 4 days, P = 0.033). In multivariate analysis, synchronous CRC was an independent prognostic factor associated with poor OS (hazard ratio: 2.355, 95% confidence interval: 1.322–4.195, P = 0.004), DFS (hazard ratio: 2.079, 95% confidence interval: 1.261–3.429, P = 0.004), and CSS (hazard ratio: 2.429, 95% confidence interval: 1.313–4.493, P = 0.005).

**Conclusion** The clinical and pathological features exhibit differences between synchronous CRC and solitary CRC and the prognosis of patients with synchronous CRC was poorer than those with solitary CRC. Eur J Gastroenterol Hepatol 31: 1489–1495 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.

## Introduction

Colorectal cancer (CRC) is the fourth most common carcinoma with an increasing incidence in China [1]. In addition, comparing to solitary tumors, synchronous colorectal carcinoma (synchronous CRC) is a rare type of colorectal malignancy, which is defined as more than one primary colorectal carcinoma detected in one patient at the time of initial presentation [2]. The range of prevalence is 1.1%– 8.1% of all colorectal cancers [3]. Synchronous CRC is often seen in males, and a previous large-scale study determined the male/female ratio as 1.85 [4]. The other known

European Journal of Gastroenterology & Hepatology 2019, 31:1489–1495 Keywords: prognosis, solitary colorectal carcinoma,

synchronous colorectal carcinoma

<sup>a</sup>Department of Gastrointestinal Surgery, The People's Hospital of Leshan, Leshan and <sup>b</sup>Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China

Correspondence to Ziqiang Wang, PhD, MD, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guoxue Street, Chengdu 610041, China

Tel: +86 028 85422480; fax: +86 028 81654035; e-mail: wangziqiang@scu.edu.cn Wanbin He and Chengjun Zheng are senior co-authors.

Received 16 January 2019 Accepted 5 June 2019

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NCND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. higher risk factors include inflammatory bowel diseases, Lynch syndrome, familial adenomatous polyposis, and adenomas/hyperplasic polyposis [5–8]. Moreover, the chromosomal instability, microsatellite instability (MSI), and gene methylation account for various predisposing lesions or factors for synchronous CRC [9].

Although synchronous CRC is identified as a significant entity at the clinical and molecular level, the clinical and pathological features and prognosis are yet controversial [5]. In addition, the results of previous studies which evaluated the prognostic significance of synchronous CRC are conflicting. Thus, the common consensus is reached on the occurrence of synchronous CRC as an independent predictive factor of survival as compared to solitary CRC after the operation [5,10,11]; the expected long-term survival rates of patients with synchronous CRC are yet controversial [12].

The present study aimed to compare the various clinicopathological features and short-term/long-term cancer-specific outcomes between synchronous and solitary CRC by a matched pair analysis with stratification based on age, sex, American Society of Anesthesiologists (ASA) class, BMI, cancer grade, tumor location, and tumor stage.

# Methods

## **Patients**

This study was approved by the Ethics Committee of West China Hospital of Sichuan University, and the need for

0954-691X Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. DOI: 10.1097/MEG.00000000001487 1489

Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

informed consent was waived. The study was evaluated by the STROBE statement [13]. A retrospective review of 5742 patients who underwent surgery for colorectal cancer between October 2009 and June 2013 obtained from the database of the Department of Gastrointestinal Surgery of West China Hospital of Sichuan University. A total of 131 (2.8%) patients were diagnosed with synchronous CRC at the time of initial presentation. Of these, five patients who received only enterostomy owing to the tumors did not achieve an R0 reaction, and hence, were excluded from this study. Finally, 126 patients who underwent curative surgery were included in the present study. All the patients accepted colonoscopy. Computed tomography (CT) or magnetic resonance imaging (MRI) was implied to evaluate the resectability before the surgery.

#### Matched pair analysis

Each patient with synchronous CRC and a control group of patients with solitary CRC who underwent radical surgery of colon cancer or total mesorectal excision were matched in pairs at a ratio of 1:1. The case-matched criteria included age (± 5 years), sex, ASA class, BMI (± 5 kg/m<sup>2</sup>), cancer grade, tumor location, and tumor stage. In this study, the time of surgery was not considered as a criterion as some patients could not be contacted for follow-up. Thus, the operation time of the control group was restricted to the same period as that of the synchronous CRC group, and the location of the tumor was only matched by two sites: colon and rectum. The pathological stage was determined according to the 7th edition of the American Joint Committee on Cancer staging manual [14]. Matching cancer stage of synchronous CRC was categorized according to the most advanced tumor, and the N-stage was determined based on all lymph nodes.

#### Treatment

Either laparoscopic resection or conversion to open surgery was applied by colorectal surgeons who were experienced in colorectal and laparoscopic or conventional surgery. Patients with colon cancer underwent right-sided resections (including the transverse colon), left non-sigmoid resections (including the left colon flexure and the descending colon), or sigmoid resections. The resections of the rectosigmoid junction included a part of the rectum and total mesorectal excision was performed on patients with rectal cancer. Side-to-end anastomosis was used to construct the stoma in the right-sided resections, while straight anastomosis was used in the other resections. All the operations followed the principle: lymphadenectomy and circumferential margins were cleared.

#### Assessment parameters

The short-term outcomes included the length of hospital stay, complications, and 30-day mortality. Long-term endpoints were overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS). OS was defined as the period from the date of surgery to the date of death from any cause. DFS was defined as the period from the date of surgery to the date of tumor recurrence or distant metastasis. CCS was defined as the period from the date of surgery to the date of death from cancer. The local recurrence was defined as the recurrent disease in the pelvis, while distant recurrence was defined as the recurrence outside of the pelvis. The patients acquired a peritoneal or pelvic sepsis postoperatively, which should be treated by a second operation that was defined as anastomotic leakage.

## Follow-up

All patients were followed-up every 6 months in the initial 3 years and every 12 months thereafter. The clinical evaluations included a complete blood count, liver and kidney function test, serum carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 levels, physical examination (conducted at each visit), CT scan of the abdomen, chest, and pelvis, and colonoscopy (conducted every 12 months). In addition, MRI of the upper abdomen was performed when the patients were suspected with liver metastasis.

#### Statistical analysis

The categorical variables were presented as absolute and relative frequencies which were analyzed by the chisquared or Fisher's exact probability test. Quantitative variables were reported as mean ± SD and compared by the nonparametric Mann-Whitney U test. Odds ratios (ORs) and 95% confidence intervals (CIs) were used as standard measures to quantify the strength of the association between exposure and outcome. The survival curves were calculated using the Kaplan-Meier method and statistical significance were determined by the log-rank test. Univariate and multivariate analyses were conducted using Cox proportional hazards models with the putative clinicopathological parameters included in this analysis. Hazard ratios (HRs) and 95% CIs were used as common measures to assess the relative risk. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 22.0 (IBM Co., Armonk, New York, USA). A probability (*P*)-value < 0.05 was considered statistically significant.

#### **Results**

#### **Demographic data**

The present study included 252 (66.7%) patients containing 84 females and 168 males. The mean age of the patients at the time of diagnosis was  $62.57 \pm 12.63$  years for all patients,  $62.57 \pm 12.64$  years for synchronous CRC, and  $62.55 \pm 12.27$  years for solitary CRC. The mean age of the males and females at the time of diagnosis was  $63.18 \pm 12.73$  and  $61.36 \pm 12.51$  years, respectively in synchronous CRC patients.

#### **Clinical and pathological characteristics**

The clinical and pathological characteristics of both groups are listed in Tables 1 and 2, respectively. No significant difference was detected in the age, BMI, sex, ASA score, CEA levels, adjuvant chemoradiotherapy, hospital stay, 30-day mortality, and postoperative complications between the two groups (Table 1). One patient (0.8%) died in each group because of serious pyemia and respiratory failure. Five patients (3.9%) in the synchronous CRC group and three patients (2.4%) in the solitary CRC group developed

#### Table 1. Patient characteristics

	Synchronous CRC	Solitary CRC	
	N = 126	N = 126	P value
Age, year			
< 60	47 (37.3)	49 (38.9)	0.80
≥ 60	79 (62.7)	77 (61.1)	
BMI, (mean ± SD), kg/m <sup>2</sup>	22.8 ± 3.0	$22.2 \pm 2.6$	0.30
Sex, n (%)			
Male	84 (66.7)	84 (66.7)	1.00
Female	42 (33.3)	42 (33.3)	
ASA score, n (%)			
1	7 (5.6)	14 (11.1)	0.28
Ш	96 (76.2)	91 (72.2)	
111	23 (18.3)	21 (16.7)	
CEA levels, ng/ml, n (%)		( )	0.51
<5	76 (60.3)	81 (64.3)	
≥5	50 (39.7)	45 (35.7)	
Adjuvant chemoradiotherapy	, n (%)	( )	
Yes	61 (48.4)	69 (54.8)	0.31
No	65 (51.6)	57 (45.2)	
Smoking history, n (%)		( )	
Yes	47 (37.3)	28 (22.2)	0.009
No	79 (62.7)	98 (77.8)	
Alcohol intake, n (%)		( )	
Yes	38 (30.2)	18 (14.2)	0.002
No	88 (69.8)	108 (85.7)	
Hospital stay, median,	16 (7–56)	17 (6–52)	0.10
(range), day		. ,	
Hospital stay after opera-	10 (4–31)	4 (4–28)	0.033
tion, median, (range), day			
30-day mortality, n (%)	1 (0.8)	1 (0.8)	1.00
Operative approach, n (%)		× ,	
Conventional	103 (81.7)	45 (35.7)	< 0.001
Laparoscopic	23 (18.3)	81 (64.3)	
Postoperative complica-	22 (17.5)	18 (14.3)	0.49
tions, n (%)		. ,	
Anastomotic leakage	5 (3.9)	3 (2.4)	
Would infection	3 (2.4)	1 (0.8)	
Pulmonary infection	6 (4.8)	8 (6.3)	
Gastrointestinal	2 (1.6)	2 (1.6)	
dysfunction			
Urine retention	0 (0)	1 (0.8)	
Paralytic ileus	2 (1.6)	1 (0.8)	
Chylous fistula	1 (0.8)	1 (0.8)	
Intestinal fistula	2 (1.6)	0 (0)	
Intra-abdominal bleeding	0 (0)	1 (0.8)	
Abdominal infection	1 (0.8)	0 (0)	
	· · ·	· /	

Data are presented as mean  $\pm$  SD or median (range): Mann–Whitney U test was used. All other parameters absolute numbers (%); chi-squared or Fisher's exact test. ASA, American Society of Anesthesiology; BMI, body mass index; CRC, colorectal cancer.

anastomotic leakage after the operation. The distribution of smoking history (47/126 vs. 28/126, OR: 2.082, 95% CI: 1.197–3.623, P = 0.009), alcohol intake (38/126 vs. 18/126, OR: 2.591, 95% CI: 1.383–4.852, P = 0.002), and operative approach (103/126 vs. 45/126, P < 0.001) differed significantly between two groups. However, the hospital stay after the operation of synchronous CRC was longer than that in solitary CRC (median: 10 vs. 4 days, P = 0.033).

Furthermore, no significant differences were found between the two groups with respect to tumor size, tumor location, cancer grade, depth of tumor invasion, regional lymph node status, cancer stage, cancer embolus, and perineural invasion (Table 2). The distribution of mucinous adenocarcinoma (MAC) containing signet-ring cell carcinoma (SC) (50/126 vs. 27/126, OR: 2.412, 95% CI: 1.384–4.204, P = 0.002), lymph nodes (78/126 vs. 55/126, OR: 2.098, 95% CI: 1.268–3.470, P = 0.004), polypus

#### $4.3 \pm 2.2$ $4.6 \pm 2.1$ Tumor size, mean ± SD (cm) Tumor location, n (%) 67 (53.2) 67 (53.2) Colon Rectum 59 (46.8) 59 (46.8) Cancer grade (G), n (%) G1 7 (5.6) 3 (2.4) 80 (63.5) G2 75 (59.5) G3 34 (27.0) 36 (28.6) 7 (5.6) G4 10 (7.9) Depth of tumor invasion (T), n (%) 8 (6.3) 8 (6.3) T1 T2 18 (14.3) 22 (17.5) 54 (42.9) 60 (47.6) T3 Т4 46 (36.5) 36 (28.6) Regional lymph node status (N), n (%) N0 71 (56.3) 71 (56.3) 39 (31.0) N1 33 (26.2) ND 00 (17 E) 16 (10 7)

Synchronous CRC

N = 126

Table 2. Pathological parameter

22 (17.0)	10(12.7)	
24 (19.0)	24 (19.0)	1.00
46 (36.5)	46 (36.5)	
54 (42.9)	54 (42.9)	
2 (1.6)	2 (1.6)	
containing signet-r	ing cell carcinoma. n	(%).
50 (39.7)	27 (21.4)	0.002
76 (60.3)	99 (78.6)	
78 (61.9)	55 (43.7)	0.004
48 (38.1)	71 (56.3)	
( )	· · · · ·	
57 (45.2)	11 (8.7)	< 0.001
69 (54.8)	115 (91.2)	
( )	· · · · ·	
25 (19.8)	13 (10.3)	0.035
101 (80.2)	113 (89.7)	
( )	· · · · ·	
9 (7.1)	14 (11.1)	0.27
117 (92.9)	112 (88.9)	
( )	· · · · ·	
6 (4.8)	5 (4.0)	0.76
120 (95.2)	121 (96.0)	
	22 (11.3) 24 (19.0) 46 (36.5) 54 (42.9) 2 (1.6) containing signet-r 50 (39.7) 76 (60.3) 78 (61.9) 48 (38.1) 57 (45.2) 69 (54.8) 25 (19.8) 101 (80.2) 9 (7.1) 117 (92.9) 6 (4.8) 120 (95.2)	22 (11.5)         10 (12.7)           24 (19.0)         24 (19.0)           46 (36.5)         46 (36.5)           54 (42.9)         54 (42.9)           2 (1.6)         2 (1.6)           containing signet-ring cell carcinoma, n           50 (39.7)         27 (21.4)           76 (60.3)         99 (78.6)           78 (61.9)         55 (43.7)           48 (38.1)         71 (56.3)           57 (45.2)         11 (8.7)           69 (54.8)         115 (91.2)           25 (19.8)         13 (10.3)           101 (80.2)         113 (89.7)           9 (7.1)         14 (11.1)           117 (92.9)         112 (88.9)           6 (4.8)         5 (4.0)           120 (95.2)         121 (96.0)

Data are presented as mean  $\pm$  SD: Mann–Whitney *U* test was used. All other parameters absolute numbers (%): chi-squared or Fishers exact test. CRC, colorectal cancer.

(57/126 vs. 11/126, OR: 8.636, 95% CI: 4.241-17.586, P < 0.001), and tumor deposit (25/126 vs. 13/126, OR: 2.152, 95% CI: 1.045-4.429, P = 0.035) was significantly different between the two groups.

In 38 (30.2%) patients, both tumors were localized in the colon, and in 41 (32.5%) patients, both tumors were detected in the rectum. A total of 47 (37.3%) patients had two tumors localized separately in colon and rectum (Table 3).

#### Survival analysis

The median follow-up time of all patients was 42.5 (range, 1–85) months, while that for synchronous CRC and solitary CRC was 38 (range, 1–74) month and 46 (range, 1–85) months, respectively. The Kaplan–Meier survival curves for OS, DFS, and CSS of the two groups are shown in Fig. 1a, b, and c. The 3- and 5-year OS rates in synchronous CRC group were 74.3  $\pm$  4.2% and 65.7  $\pm$  5.6% and those in the solitary CRC group were 86.8  $\pm$  3.2% and 81.6  $\pm$  4.2%, respectively (P = 0.009). The 3- and

Solitary CRC

N = 126

P value

0 19

1.00

0.50

0.59

0.49

Table 3. Distribution of sy	nchronous (	colorectal tumors
-----------------------------	-------------	-------------------

Synchronous colorectal tumors	n (%)
Right hemicolon-right hemicolon	12 (9.5)
Right hemicolon-left hemicolon	13 (10.3)
Right hemicolon-rectum	18 (14.3)
Left hemicolon-left hemicolon	13 (10.3)
Left hemicolon-rectum	29 (23.0)
Rectum-rectum	41 (32.5)

Right hemicolon = cecum to hepatic flexure; left hemicolon = transverse colon to sigmoid colon.

5-year DFS rates in synchronous CRC group were 68.1  $\pm$  4.5% and 55.4  $\pm$  6.8% and those in the solitary CRC group were 82.9  $\pm$  3.5% and 75.7  $\pm$  4.5%, respectively (*P* = 0.009). The 3- and 5-year CSS rates in synchronous CRC group were 76.5  $\pm$  4.1% and 67.7  $\pm$  5.6% and those in the solitary CRC group were 87.5  $\pm$  3.1% and 83.5 $\pm$  4.1%, respectively (*P* = 0.01).

#### Univariate and multivariate analysis

The results of the univariate analysis showed that age, sex, ASA score, location of tumor, MAC containing SC, lymph nodes, polypus, cancer embolus, postoperative complications, tumor size, smoking history, and alcohol intake were not associated with the OS, DFS, and CSS (Table 4). CEA levels (HR: 2.141, 95% CI: 1.240-3.679, *P* = 0.006; HR: 1.868, 95% CI: 1.150–3.035, *P* = 0.012; HR: 2.271, 95% CI: 1.278-4.037, P = 0.005), cancer grade (HR: 3.296, 95% CI: 1.902–5.711, *P* < 0.001; HR: 2.444, 95% CI: 1.505–3.970, P < 0.001; HR: 3.239, 95% CI: 1.818–5.770, *P* < 0.001), regional lymph node status (HR: 4.956, 95% CI: 2.678–9.173, P < 0.001; HR: 4.226, 95% CI: 2.492–7.169, P < 0.001; HR: 4.331, 95% CI: 2.311-8.117, P < 0.001), cancer stage (HR: 4.704, 95%) CI: 2.543–8.704, P < 0.001; HR: 4.008, 95% CI: 2.363– 6.797, P < 0.001; HR: 4.109, 95% CI: 2.193-7.698, P < 0.001), tumor deposit (HR: 4.095, 95% CI: 2.261-7.417, *P* < 0.001; HR: 3.624, 95% CI: 2.097–6.263, *P* < 0.001; HR: 4.816, 95% CI: 2.618-8.859, P < 0.001), perineural invasion (HR: 4.308, 95% CI: 1.529–12.137, P = 0.006; HR: 3.488, 95% CI: 1.386-8.781, P = 0.008; HR: 3.608, 95% CI: 1.103–11.808, P = 0.034), and synchronous CRC (HR: 2.098, 95% CI: 1.190–3.697, P = 0.010; HR: 1.906, 95% CI: 1.161–3.129, P = 0.011; HR: 2.141, 95% CI: 1.178-3.829, P = 0.013) were associated with OS, DFS, and CSS, respectively. On the other hand, the depth of tumor invasion (HR: 2.304, 95% CI: 1.037–5.119, P = 0.041; HR: 2.025, 95% CI: 1.031-3.978, P = 0.040) was associated with OS and DFS, respectively, and the adjuvant chemoradiotherapy (HR: 2.052, 95% CI: 1.111-3.790, P = 0.022) was associated with CSS.

Multivariate analysis was performed to assess the prognostic value of factors with P < 0.05 in univariate analysis for OS, DFS, and CSS (Table 5). Cancer grade (HR: 3.336, 95% CI: 1.907–5.835, P < 0.001; HR: 2.434, 95% CI: 1.488–3.984, P < 0.001; HR: 2.879, 95% CI: 1.574–5.267, P = 0.001), regional lymph node status (HR: 4.231, 95% CI: 2.264–7.907, P < 0.001; HR: 3.778, 95% CI: 2.209–6.460, P < 0.001; HR: 2.854, 95% CI: 1.418–5.747, P = 0.003), CEA levels  $\geq$  5 ng/ml (HR: 1.912, 95% CI: 1.095–3.340, P = 0.023; HR: 1.659, 95% CI: 1.012–2.720, P = 0.045; HR: 2.017, 95% CI: 1.122–3.624, P = 0.019), and synchronous CRC (HR: 2.355, 95% CI: 1.322–4.195, P = 0.004; HR: 2.079, 95% CI: 1.261–3.429, P = 0.004; HR: 2.429, 95% CI: 1.313–4.493, P = 0.005) were independent prognostic factors of OS, DFS, and CSS, respectively.

#### Discussion

The present study compared the prognosis of patients with synchronous and solitary in a matched pair analysis. The synchronous CRC, which accounted for 2.8% of all colorectal carcinomas, was an independent prognostic factor for CRC. Comparing to solitary CRC, patients with synchronous CRC had worse long-term OS, DFS, and CSS rates. Cancer grade and regional lymph node status were also correlated with poor OS, DFS, and CSS, while the CEA levels ( $\geq$  5 ng/ml) were associated with poor OS and CSS.

Lam *et al.* [3] reported an overall incidence of 3.5% (3667/105686) of synchronous CRC based on the data from 39 studies. The prevalence of synchronous CRC was < 3.5% in the current study. This phenomenon can be explained by the fact that non-uniform definition and interchanging of synchronous CRC and metachronous CRC [15]. On the other hand, the higher risk of inflammatory bowel diseases was much less common in Asia than in the West, and a lower overall prevalence rate of 2.2% UC-related CRC as compared to the 3%-5% in Western countries [16]. Lynch syndrome also accounted for 5.6%-6.4% of all CRC patients in China [17].

Furthermore, the mean of diagnosis was 62.57 years, which was in concordance with that reported previously [3], and the mean age of the males was higher than that of females (63.18 vs. 61.36 years). With respect to sex, Foster's study demonstrated a robust association between estrogen activity and metabolism with CRC [18], indicating that the proportion of females with synchronous CRC was less than the males. The risk factors of CRC including family history of colorectal cancer, smoking, excessive alcohol consumption, high consumption of red and processed meat, obesity, and diabetes [19], may also be associated with synchronous CRC. In the current study, smoking history (OR: 2.082, 95% CI: 1.197-3.623) and alcohol intake (OR: 2.591, 95% CI: 1.383-4.852) may lead to a higher risk in patients with synchronous CRC as compared to those with solitary CRC.

Surgery was challenging for synchronous CRC because the tumors were distantly localized. Although colonoscopy can detect and effectively remove the promalignant and malignant lesions [20], it not used commonly in patients with CRC or synchronous CRC. Thus, extensive bowel resection such as total or subtotal colectomy was required in such cases [11]. A previous study reported that patients with synchronous CRC underwent an extensive resection in some cases [15]. In 60 (47.6%) patients, the tumors were localized in different sites, and 103 (81.7%) patients with synchronous CRC accepted open surgery and hospital stay after the surgery duration was longer than that for solitary CRC (median 10 vs. 4 days), which indicated that extended surgical resection is often required in synchronous CRC. Table 4. Univariate analysis of clinicopathological parameters for the prediction of overall survival, disease-free survival, and cancer-specific survival

Clinicoputhological purameter         N         HR         05% CI         Paule         HR         05% CI         Paule         HR         05% CI         Paule           App., year C 0 0         00         156 (R1 9)         1.167         0.670-210         0.68         0.677         0.333-142         0.58         Reference 0.433-142         0.585-1.82         0.585-1.82         0.585-1.82         0.585-1.82         0.585-1.82         0.585-1.82         0.585-1.82         0.585-1.82         0.585-1.82         0.585         0.585-1.82         0.585-1.82         0.585         0.585-1.82         0.585         0.585-1.82         0.585         0.585-1.82         0.515-1.82         0.585         0.575-1.82         0.55         0.575-1.82         0.56         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585         0.585			OS		DFS			CSS			
App. yard S CD         Set (31) (56) (51)         Reference (53)         Reference (53)         Reference (53)         Reference (53)         Reference (54)         Reference (55)         Ref	Clinicopathological parameter	Ν	HR	95% CI	P value	HR	95% Cl	P value	HR	95% CI	P value
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Age, year										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	< 60	96 (38.1)	Reference			Reference			Reference		
Sex. n (%)         Batemace         Reference         Reference <t< td=""><td>≥ 60</td><td>156 (61.9)</td><td>1.187</td><td>0.670-2.102</td><td>0.58</td><td>0.871</td><td>0.533–1.423</td><td>0.58</td><td>1.015</td><td>0.563–1.828</td><td>0.96</td></t<>	≥ 60	156 (61.9)	1.187	0.670-2.102	0.58	0.871	0.533–1.423	0.58	1.015	0.563–1.828	0.96
Male         166 (62,7)         Reference         R	Sex, n (%)										
Fernale         84 (33, 3)         1.385         0.780-2.87         0.28         1.139         0.686-1.890         0.81         1.482         0.828-2.866         0.19           SAS score, (15)         21 (8.3)         Federance         Reference         Reference         Reference         Reference         Score         0.693         0.281-1.899         0.47         0.376         0.109-1.303         0.12           C5         157 (62.3)         Reference         Re	Male	168 (66.7)	Reference			Reference			Reference		
Base accore, n (ns)         Peteranco         Peteranco         Peteranco         Peteranco         Peteranco         Peteranco         Peteranco           II         197 (74.2)         0.070         0.279-1.001         0.47         0.615         0.494         0.636         0.626         0.251-1.839         0.47         0.2378         0.102-1.303         0.102           CAL lavels, ng/ml, n (%)         157 (62.3)         Reference         2.271         1.278-4.037         0.005           S.5         95 (62.7)         2.141         1.240-5.71         0.005         2.444         1.525-3.377         0.001         3.239         1.818-5.77         0.005           Depth of function invasion (T), n (%)         717.2         66 (22.2)         Reference         Reference         1.031-3.378         0.040         2.050         0.323-4.607         0.001           T17.2         66 (22.2)         Reference         Reference         Reference         1.031-3.378         0.040         2.050         0.920-4.607         0.001           NINZ         104 (5.7)         Reference         Reference         Reference         1.020         0.011         4.318         2.311-8.117         0.001           Cancer stage, n (%)         110 (5.5)         Reference	Female	84 (33.3)	1.365	0.780-2.387	0.28	1.139	0.686–1.890	0.61	1.482	0.828-2.656	0.19
1         21 (6.5)         network         2.72–1.801         0.47         Data         Data <thdata< th=""> <thdata< th="">         Data</thdata<></thdata<>	ASA score, n (%)	01 (0.0)	Deference			Deference			Deference		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1	21 (0.3)	A ZOO	0.070 1.901	0.47	Reference	0.240 1.002	0.64	Reference	0.060 1.701	0.40
Circle Auesis, ng/ml, n (%)         15 (10.5)         0.007	11 111	107 (14.2)	0.709	0.279-1.001	0.47	0.815	0.349-1.902	0.04	0.000	0.202-1.701	0.40
	CFA levels, ng/ml, n (%)	44 (17.3)	0.010	0.133-1.003	0.00	0.030	0.201-1.000	0.47	0.070	0.103-1.000	0.12
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	<5	157 (62.3)	Reference			Reference			Reference		
Cancer grade (G), n (%) G1/G2 165 (6.5.) Reference C G3/G4 87 (34.5) 3.286 1.902-5.71 <0.001 Performation invasion (D, n (%) T1/T2 56 (2.2.) Reference C T3/T4 196 (7.7) 2.304 1.337-5.119 0.041 2.025 1.031-3.978 0.040 2.299 0.920-4.607 0.08 Reference C T3/T4 196 (7.7) 2.304 1.337-5.119 0.041 2.025 1.031-3.978 0.040 2.299 0.920-4.607 0.08 Reference C NN 0 142 (6.3.) Reference C NN 0 142 (6.3.) Reference C NN 0 124 (4.4) 4.704 2.543-8.704 0.001 4.226 2.492-7.169 0.001 4.331 2.311-8.117 0.001 Cancer stage, n (%) III 104 (3.7) 4.965 0.747-2.246 0.38 1.408 2.439-7.000 4.205 1.031-3.978 0.040 2.511-8.119 0.001 Cancer stage, n (%) III 144 (4.5) Reference C Reference C Colon 134 (5.3.2) 1.295 0.747-2.246 0.38 1.328 0.813-2.170 0.26 1.092 0.610-1.920 0.79 Nucinous adenocarchine a containing signer-ting cell carcinoman, n (%) No 172 (0.9.4) Reference C Colon 134 (5.3.2) 1.295 0.747-2.246 0.38 1.328 0.813-2.170 0.26 1.082 0.610-1.920 0.79 Nucinous adenocarchine a containing signer-ting cell carcinoman, n (%) No 177 (0.9.6 0.956 0.571-1.769 0.88 1.1103 0.825-1.867 0.72 0.785 0.404-1.564 0.51 No d1 Namples, n (%) 77 (0.9.6 0.956 0.571-1.769 0.88 1.103 0.825-1.867 0.72 0.785 0.404-1.564 0.51 No d1 Namples, n (%) 77 (0.9.6 0.956 0.571-1.769 0.88 1.103 0.825-1.867 0.72 0.785 0.404-1.564 0.51 No d1 Namples, n (%) 116 (4.7.9 1.110 0.644-1.915 0.71 1.626 0.665-1.721 0.81 0.885 0.555-1.747 0.96 Perference Molus, n (%) 214 Reference M No 214 (8.6.8) Reference M No 214 Reference M No 214 (8.6.8)	≥5	95 (36.7)	2.141	1.240-3.679	0.006	1.868	1.150-3.035	0.012	2.271	1.278-4.037	0.005
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Cancer grade (G), n (%)										
G3/G4         87 (34.5)         3.296         1.902-5.711         <0.001	G1/G2	165 (65.5)	Reference			Reference			Reference		
	G3/G4	87 (34.5)	3.296	1.902–5.711	<0.001	2.444	1.505–3.970	<0.001	3.239	1.818–5.770	<0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Depth of tumor invasion (T), n (%	b)	5 (			5 (			5 (		
13-14         139         103         2.304         103         2.303         0.301         2.303         0.301         2.303         0.301         0.301           NO         142 (53.3)         Reference         Reference         Reference         Reference         Reference         Reference         1.331         2.311-8.117         <0.001	11/12	56 (22.2)	Reference	1 007 5 110	0.041	Reference	1 001 0 070	0.040	Reference	0.000 4.607	0.00
No.         142 (56.3)         Reference         Reference         Reference         Reference         Reference           M1/N2         110 (43.7)         4.956         2.678-9.173         <0.001	Regional lymph node status (N)	190 (77.0) n (%)	2.304	1.037-5.119	0.041	2.025	1.031-3.976	0.040	2.059	0.920-4.607	0.08
Ni Nu2         110 (43.7)         4.956         2.678-9.173         <0.001         4.226         2.492-7.169         <0.001         4.331         2.311-8.117         <0.001           Cancer stage, n (%)         112 (44.4         4.704         2.543-8.704         <0.001         4.008         2.363-6.797         <0.001         4.109         2.193-7.698         <0.001           Colon         112 (44.4         4.704         2.543-8.704         <0.001         4.008         2.363-6.797         <0.001         4.109         2.193-7.698         <0.001           Colon         114 (44.8)         Reference         Colon         1.328         0.747-2246         0.36         1.328         0.813-2.170         0.26         1.028         0.610-1.920         0.79           Mucinous adenocarcinoma containing signet-ring cell carcinoma, n (%)         No         175 (69.4)         Reference	NO	142 (56.3)	Reference			Reference			Reference		
Cancer stage, n (%)         Cancer stage, n (%)         Cancer stage, n (%)         Cancer stage, n (%)         Reference         Reference <td>N1/N2</td> <td>110 (43.7)</td> <td>4.956</td> <td>2.678-9.173</td> <td>&lt; 0.001</td> <td>4.226</td> <td>2.492-7.169</td> <td>&lt; 0.001</td> <td>4.331</td> <td>2.311-8.117</td> <td>&lt; 0.001</td>	N1/N2	110 (43.7)	4.956	2.678-9.173	< 0.001	4.226	2.492-7.169	< 0.001	4.331	2.311-8.117	< 0.001
I/II         140 (55.6)         Feference         Reference         Reference         Reference           I/I/V         112 (44.4)         4.704         2.543-8.704         <0.001	Cancer stage, n (%)										
III/V         112 (44.4)         4.70         2.543-8.704         <0.001         4.008         2.363-6.797         <0.001         4.109         2.193-7.698         <0.001           Decision of the synchronous tumor, n (%)         124 (53.2)         1.295         0.747-2246         0.36         1.328         0.813-2.170         0.26         1.082         0.610-1.920         0.79           Mucinous adenocarcinoma containing signet-ring cell carcinoma, n (%)         No         175 (69.4)         Reference         Reference         Reference         Reference         Reference         1.032         0.625-1.867         0.72         0.795         0.404-1.564         0.51           No. of LN samples, n (%)         112         1.101         0.644-1.915         0.71         1.062         0.655-1.721         0.81         0.862         0.57         0.795         0.404-1.564         0.51           No. of LN samples, n (%)         1.371         0.767-2.49         0.29         1.599         0.968-2.642         0.07         1.200         0.642-2.245         0.57           Tumor deposit, n (%)         229 (90.9)         Reference         Reference         Reference         Reference         Reference         No         2.618-8.659         <0.001	1/11	140 (55.6)	Reference			Reference			Reference		
Laceation of the synchronous tumor, n(%) Rectum 18 (46.8) Reference 18 (46.8) Reference 0.747-2246 0.36 1.328 0.813-2.170 0.26 1.082 0.610-1.920 0.79 Mucinous adenocarcinoma containing signet-ting cell carcinoma, n (%) No 175 (69.4) Reference 79 8 77 (30.6) 0.956 0.517-1.769 0.89 1.103 0.625-1.867 0.72 0.79 0.404-1.564 0.51 No. of LN samples, n (%) 212 133 (52.8) Reference Reference 72 8 8 8 1.103 0.625-1.867 0.72 0.79 0.404-1.564 0.51 212 133 (52.8) Reference 8 8 8 1.103 0.625-1.871 0.81 0.985 0.555-1.747 0.96 Polypus, n (%) No 119 (47.2) 1.110 0.644-1.915 0.71 1.062 0.655-1.721 0.81 0.985 0.555-1.747 0.96 Polypus, n (%) No 214 Reference 8 8 6 (27.0) 1.371 0.767-2.449 0.29 1.599 0.968-2.642 0.07 1.200 0.642-2.245 0.57 Tumor deposit, n (%) No 214 Reference 8 8 6 (27.0) 1.371 0.767-2.449 0.29 1.599 0.968-2.642 0.07 1.200 0.642-2.245 0.57 Tumor deposit, n (%) No 214 Reference 8 8 6 (27.0) 1.371 0.767-2.449 0.29 1.599 0.968-2.642 0.07 1.200 0.642-2.245 0.57 Tumor deposit, n (%) No 214 Reference 8 8 6 (27.0) 1.371 0.767-2.449 0.29 1.599 0.968-2.642 0.07 1.200 0.642-2.245 0.57 Tumor deposit, n (%) No 214 Reference 8 8 6 (27.0) 1.371 0.767-2.49 0.29 1.599 0.968-2.642 0.07 1.200 0.642-2.245 0.57 Tumor deposit, n (%) No 229 (90.9) Reference 8 8 6 (27.0) 1.365 0.667-3.672 0.30 1.180 0.509-2.732 0.70 1.748 0.740-4.125 0.20 Perineural invasion, n (%) No 2241 (95.6) Reference 8 8 6 (27.0) 1.463 0.488 1.386-8.781 0.008 3.608 1.103-11.808 0.034 Adjuvant chemoradiotherap, n (%) No 122 (48.4) Reference 8 8 6 (27.0) 1.463 0.488 1.386-8.781 0.008 3.608 1.103-11.808 0.034 Adjuvant chemoradiotherap, n (%) No 122 (48.4) Reference 8 8 6 6 (27.0) 1.453 0.889-2.374 0.14 2.052 1.111-3.790 0.022 Postopartive complications, n (%) No 122 (48.4) Reference 8 8 6 6 (27.0) 1.453 0.889-2.374 0.14 2.052 1.111-3.790 0.022 Postopartive complications, n (%) No 122 (8.60) 2.098 1.190-3.697 0.010 1.453 0.692-2.746 0.46 1.208 0.690-2.182 0.692-1.82 0.692-1.82 0.692-1.82 0.692-1.82 0.692-1.82 0.692-1.82 0.692-1.82 0.692-1	III/IV	112 (44.4)	4.704	2.543-8.704	<0.001	4.008	2.363-6.797	<0.001	4.109	2.193–7.698	< 0.001
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Location of the synchronous turn	nor, n (%)									
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Rectum	118 (46.8)	Reference			Reference			Reference		
No         175 (69.4)         Reference         Refe	Colon	134 (53.2)	1.295	0.747-2.246	0.36	1.328	0.813-2.170	0.26	1.082	0.610–1.920	0.79
No         173 (0.5.1)         Neisence         Reference         0.72         0.735         0.404-1.564         0.51           No. of LN samples, n (%)         113         0.625-1.867         0.72         0.795         0.404-1.564         0.51           Stat         133 (52.8)         Reference         Reference         Reference         Reference         Reference         0.722         0.795         0.404-1.564         0.51           Olypus, n (%)         110         0.644-1.915         0.71         1.062         0.655-1.721         0.81         0.985         0.555-1.747         0.96           Polypus, n (%)         184 (73.0)         Reference         Reference         Reference         Reference         Reference         0.642-2.245         0.57         0.57           Tumor deposit, n (%)         229 (9.0)         Reference         Reference         Reference         Reference         Reference         2.618-8.859         <0.001	No	175 (60 /l)	Poforonco	rcinoma, n (%)		Poforonco			Poforonco		
No. of LN samples, n (%)       No. of LN samples, n (%)       No. of LN samples, n (%)       Reference       Reference       Reference         <12	Yes	77 (30.6)	0.956	0 517-1 769	0.89	1 103	0 625-1 867	0 72	0 795	0 404-1 564	0.51
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	No. of LN samples, n (%)	11 (00.0)	0.000	0.017 1.700	0.00	1.100	0.020 1.007	0.72	0.755	0.404 1.004	0.01
<12	≥12	133 (52.8)	Reference			Reference			Reference		
Polypus, n (%)         No         184 (73.0         Reference         Reference <th< td=""><td>&lt;12</td><td>119 (47.2)</td><td>1.110</td><td>0.644-1.915</td><td>0.71</td><td>1.062</td><td>0.655-1.721</td><td>0.81</td><td>0.985</td><td>0.555-1.747</td><td>0.96</td></th<>	<12	119 (47.2)	1.110	0.644-1.915	0.71	1.062	0.655-1.721	0.81	0.985	0.555-1.747	0.96
No184 (73.0) YesReferenceReferenceReferenceReferenceYes68 (27.0)1.3710.767-2.4490.291.5990.968-2.6420.071.2000.642-2.2450.57No214ReferenceReferenceReferenceReferenceReferenceReferenceReferenceNo2.0972.0104.8162.018-8.59<0.010	Polypus, n (%)										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	No	184 (73.0)	Reference			Reference			Reference		
No         214         Reference	Yes	68 (27.0)	1.371	0.767–2.449	0.29	1.599	0.968–2.642	0.07	1.200	0.642-2.245	0.57
No         214         Hererence         Hererence         Hererence         Hererence         Hererence         Hererence         Hererence         Hererence         Cancer         Cancer         Scale         2.097–6.263         <0.001         4.816         2.618–8.859         <0.001           Cancer embolus, n (%)         No         229 (90.9)         Reference         Reference         Reference         Reference         Reference         Reference         No         229 (90.9)         No         23 (9.1)         1.565         0.667–3.672         0.30         1.180         0.509–2.732         0.70         1.748         0.740–4.125         0.20           Perineural invasion, n (%)         241 (95.6)         Reference         Reference         Reference         Reference         No         11 (4.4)         4.308         1.529–12.137         0.006         3.488         1.386–8.781         0.008         3.608         1.103–11.808         0.034           Adjuvant chemoradiotherapy, n (%)         No         122 (48.4)         Reference         Reference         Reference         Yes         1.30 (51.6)         1.666         0.947–2.930         0.07         1.453         0.889–2.374         0.14         2.052         1.111–3.790         0.022           Postoperative comp	lumor deposit, n (%)	014	Defenses			Defenses			Defenses		
Test       Solid       4.353       2.2017,4.77       Co.001       3.024       2.057-0.203       Co.001       4.310       2.010-0.203       Co.001         No       229 (90.9)       Reference       Reference       Reference       Reference         Yes       23 (9.1)       1.565       0.667-3.672       0.30       1.180       0.509-2.732       0.70       1.748       0.740-4.125       0.20         Perineural invasion, n (%)       No       241 (95.6)       Reference       Reference       Reference       Reference         Yes       11 (4.4)       4.308       1.529-12.137       0.006       3.488       1.386-8.781       0.008       3.608       1.103-11.808       0.034         Adjuvant chemoradiotherap, n (%)       No       122 (48.4)       Reference       Reference       Reference       Reference       No       1.03-11.808       0.034         Postoperative complications, n (%)       No       209       Reference       Reference       Reference       Reference       No       1.066       0.947-2.930       0.07       1.453       0.889-2.374       0.14       2.052       1.111-3.790       0.022         Postoperative complications, n (%)       No       126 (50.0)       Reference       Reference	NO	214	A 005	2 261 7 417	<0.001	Reference	2 007 6 263	<0.001	A 916	2 619 9 950	<0.001
No         229 (90.9)         Reference         Reference         Reference         Reference         Reference           Yes         23 (9.1)         1.565         0.667–3.672         0.30         1.180         0.509–2.732         0.70         1.748         0.740–4.125         0.20           Perineural invasion, n (%)	Cancer embolus n (%)	30	4.095	2.201-7.417	<0.001	3.024	2.097-0.203	<0.001	4.010	2.010-0.009	<0.001
Yes       23 (9,1)       1.565       0.667–3.672       0.30       1.180       0.509–2.732       0.70       1.748       0.740–4.125       0.20         Perineural invasion, n (%)       No       241 (95.6)       Reference       Reference       Reference       3.488       1.386–8.781       0.008       3.608       1.103–11.808       0.034         Adjuvant chemoradiotherapy, n (%)       No       122 (48.4)       Reference       Reference       Reference       3.488       1.386–8.781       0.008       3.608       1.103–11.808       0.034         Adjuvant chemoradiotherapy, n (%)       No       122 (48.4)       Reference       Reference       Reference       3.488       1.386–8.781       0.008       3.608       1.103–11.808       0.034         Postoperative complications, n (%)       No       120 (48.4)       Reference       Reference       Reference       1.111–3.790       0.022         Synchronous CRC, n (%)       No       1.266 (50.0)       Reference       Reference       Reference       2.046       1.208       0.669–2.182       0.53         Synchronous CRC, n (%)       No       126 (50.0)       Reference       Reference       Reference       2.111       1.178–3.829       0.013         Tumor size, cm, n (%)	No	229 (90.9)	Reference			Reference			Reference		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Yes	23 (9.1)	1.565	0.667-3.672	0.30	1.180	0.509-2.732	0.70	1.748	0.740-4.125	0.20
No         241 (95.6)         Reference         Reference         Reference         Reference           Yes         11 (4.4)         4.308         1.529–12.137         0.006         3.488         1.386–8.781         0.008         3.608         1.103–11.808         0.034           Adjuvant chemoradiotherapy, n (%)	Perineural invasion, n (%)	( )									
Yes       11 (4.4)       4.308       1.529–12.137       0.006       3.488       1.386–8.781       0.008       3.608       1.103–11.808       0.034         Adjuvant chemoradiotherapy, n (%)       No       122 (48.4)       Reference       1.111–3.790       0.022         Postoperative complications, n (%)       209       Reference       Reference       Reference       Reference       Reference       Reference       1.111–3.790       0.022         Yes       33       1.093       0.548–2.179       0.80       1.248       0.691–2.252       0.46       1.208       0.669–2.182       0.53         Synchronous CRC, n (%)       No       126 (50.0)       Reference       Refere	No	241 (95.6)	Reference			Reference			Reference		
Adjuvant chemoradiotherapy, n (%)       Reference       Reference       Reference       Reference         Yes       130 (51.6)       1.666       0.947–2.930       0.07       1.453       0.889–2.374       0.14       2.052       1.111–3.790       0.022         Postoperative complications, n (%)        Reference       Reference       Reference       Reference       Reference       0.497–2.930       0.07       1.453       0.889–2.374       0.14       2.052       1.111–3.790       0.022         No       209       Reference       Reference       Reference       Reference       0.609–2.182       0.53         Synchronous CRC, n (%)          1.190–3.697       0.010       1.906       1.161–3.129       0.011       2.141       1.178–3.829       0.013         Tumor size, cm, n (%)          Reference       Reference       Reference       2.141       1.178–3.829       0.013         Somoking history, n (%)            0.728–2.209       0.40       1.201       0.733–1.968       0.47       1.393       0.780–2.466       0.26         Smoking history, n (%)           0.653–2.080	Yes	11 (4.4)	4.308	1.529–12.137	0.006	3.488	1.386–8.781	0.008	3.608	1.103–11.808	0.034
No       122 (48.4)       Reference       Reference       Reference       Reference         Yes       130 (51.6)       1.666       0.947-2.930       0.07       1.453       0.889-2.374       0.14       2.052       1.111-3.790       0.022         Postoperative complications, n (%)       209       Reference       Reference       Reference       Reference       Reference         Yes       43       1.093       0.548-2.179       0.80       1.248       0.691-2.252       0.46       1.208       0.669-2.182       0.53         Synchronous CRC, n (%)       No       126 (50.0)       Reference       Reference       Reference       Reference        1.178-3.829       0.013         Tumor size, cm, n (%)       2.098       1.190-3.697       0.010       1.906       1.161-3.129       0.011       2.111       1.178-3.829       0.013         Tumor size, cm, n (%)       2.5       158 (62.7)       Reference       Reference       Reference       2.5       Somoking history, n (%)       3       1.268       0.728-2.209       0.40       1.201       0.733-1.968       0.47       1.393       0.780-2.269       0.48         Alcohol intake, n (%)       No       1.77 (70.2)       Reference       Reference	Adjuvant chemoradiotherapy, n (	(%)									
Yes130 (51.6)1.666 $0.947-2.930$ $0.07$ 1.453 $0.889-2.374$ $0.14$ $2.052$ $1.111-3.790$ $0.022$ Postoperative complications, n (%)No209ReferenceReferenceReference $0.691-2.252$ $0.46$ $1.208$ $0.669-2.182$ $0.53$ Synchronous CRC, n (%)No126 (50.0)ReferenceReferenceReference $0.011$ $2.141$ $1.178-3.829$ $0.013$ Tumor size, cm, n (%)2.098 $1.190-3.697$ $0.010$ $1.906$ $1.161-3.129$ $0.011$ $2.141$ $1.178-3.829$ $0.013$ Tumor size, cm, n (%) $8eference$ Reference $8eference$ <5	No	122 (48.4)	Reference	0.047.0.000	0.07	Reference	0.000.0.074	0.4.4	Reference	4 4 4 4 0 700	0.000
No         209         Reference         Reference         Reference           Yes         43         1.093         0.548–2.179         0.80         1.248         0.691–2.252         0.46         1.208         0.669–2.182         0.53           Synchronous CRC, n (%)	Yes Destancestive complications n (	130 (51.6)	1.666	0.947-2.930	0.07	1.453	0.889-2.374	0.14	2.052	1.111-3.790	0.022
No       1093       Neterence       Interence       Interence       Interence       Interence         Yes       43       1.093       0.548–2.179       0.80       1.248       0.691–2.252       0.46       1.208       0.669–2.182       0.53         Synchronous CRC, n (%)       No       126 (50.0)       Reference       Reference       Reference       2.011       2.141       1.178–3.829       0.013         Tumor size, cm, n (%)               0.728–2.209       0.40       1.201       0.733–1.968       0.47       1.393       0.780–2.486       0.26         Smoking history, n (%)	No	200	Reference			Reference			Reference		
No       126 (50.0)       Reference       Reference       Reference         Yes       126 (50.0)       2.098       1.190-3.697       0.010       1.906       1.161-3.129       0.011       2.141       1.178-3.829       0.013         Tumor size, cm, n (%)         5       158 (62.7)       Reference       Reference       Reference         ≥5       94 (37.3)       1.268       0.728-2.209       0.40       1.201       0.733-1.968       0.47       1.393       0.780-2.486       0.26         Smoking history, n (%)       No       177 (70.2)       Reference       Reference       Reference         Yes       75 (29.8)       1.165       0.653-2.080       0.61       1.267       0.764-2.102       0.36       1.241       0.679-2.269       0.48         Alcohol intake, n (%)       No       196 (77.8)       Reference       Reference       Reference         Yes       56 (22.2)       1.107       0.591-2.076       0.75       0.863       0.478-1.557       0.62       1.145       0.594-2.208       0.69	Yes	43	1.093	0.548-2.179	0.80	1.248	0.691-2.252	0.46	1,208	0.669-2.182	0.53
No       126 (50.0)       Reference       Reference       Reference         Yes       126 (50.0)       2.098       1.190-3.697       0.010       1.906       1.161-3.129       0.011       2.141       1.178-3.829       0.013         Tumor size, cm, n (%)          Reference       Reference       Reference       0.013         <5	Synchronous CRC, n (%)			01010 21110	0.00	112 10	01001 21202	0110		01000 21102	0.00
Yes       126 (50.0)       2.098       1.190-3.697       0.010       1.906       1.161-3.129       0.011       2.141       1.178-3.829       0.013         Tumor size, cm, n (%)        5       158 (62.7)       Reference       Reference       Reference           0.013       0.733-1.968       0.47       1.393       0.780-2.486       0.26         Smoking history, n (%)       No       177 (70.2)       Reference	No	126 (50.0)	Reference			Reference			Reference		
Tumor size, cm, n (%)       Reference       Reference       Reference         <5	Yes	126 (50.0)	2.098	1.190-3.697	0.010	1.906	1.161–3.129	0.011	2.141	1.178-3.829	0.013
<5     158 (62.7)     Reference     Reference     Reference       ≥5     94 (37.3)     1.268     0.728-2.209     0.40     1.201     0.733-1.968     0.47     1.393     0.780-2.486     0.26       Smoking history, n (%)     No     177 (70.2)     Reference     Reference     Reference       Yes     75 (29.8)     1.165     0.653-2.080     0.61     1.267     0.764-2.102     0.36     1.241     0.679-2.269     0.48       Alcohol intake, n (%)     No     196 (77.8)     Reference     Reference     Reference       Yes     56 (22.2)     1.107     0.591-2.076     0.75     0.863     0.478-1.557     0.62     1.145     0.594-2.208     0.69	Tumor size, cm, n (%)										
≥5         94 (37.3)         1.268         0.728-2.209         0.40         1.201         0.733-1.968         0.47         1.393         0.780-2.486         0.26           Smoking history, n (%)         No         177 (70.2)         Reference         Reference         Reference         Reference           Yes         75 (29.8)         1.165         0.653-2.080         0.61         1.267         0.764-2.102         0.36         1.241         0.679-2.269         0.48           Alcohol intake, n (%)         No         196 (77.8)         Reference         Reference         Reference           Yes         56 (22.2)         1.107         0.591-2.076         0.75         0.863         0.478-1.557         0.62         1.145         0.594-2.208         0.69	<5	158 (62.7)	Reference			Reference			Reference		
No         177 (70.2)         Reference         Reference         Reference           Yes         75 (29.8)         1.165         0.653–2.080         0.61         1.267         0.764–2.102         0.36         1.241         0.679–2.269         0.48           Alcohol intake, n (%)	≥5	94 (37.3)	1.268	0.728-2.209	0.40	1.201	0.733–1.968	0.47	1.393	0.780-2.486	0.26
No         196 (77.8)         Reference         Reference         Reference         Reference         Reference         Reference         State	SHOKING NISTORY, N (%)	177 /70 0	Poforanaa			Deference			Deforence		
Alcohol intake, n (%)         No         196 (77.8)         Reference         Reference         Reference           Yes         56 (22.2)         1.107         0.591–2.076         0.75         0.863         0.478–1.557         0.62         1.145         0.594–2.208         0.69	NU Ves	75 (20.2)	1 165	0 653-2 080	0.61	1 267	0 764-2 102	0.36		0 679-2 260	0 / 8
No         196 (77.8)         Reference         Reference         Reference           Yes         56 (22.2)         1.107         0.591–2.076         0.75         0.863         0.478–1.557         0.62         1.145         0.594–2.208         0.69	Alcohol intake, n (%)	10 (23.0)	1.100	0.000-2.000	0.01	1.201	0.104-2.102	0.00	1.471	0.013-2.203	0.40
Yes 56 (22.2) 1.107 0.591-2.076 0.75 0.863 0.478-1.557 0.62 1.145 0.594-2.208 0.69	No	196 (77.8)	Reference			Reference			Reference		
	Yes	56 (22.2)	1.107	0.591-2.076	0.75	0.863	0.478–1.557	0.62	1.145	0.594–2.208	0.69

CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; CSS, cancer-specific survival; DFS, disease-free survival; HR, hazard ratio; OS, overall survival.

The short-term outcome did not differ significantly between the two groups. The 30-day postoperative mortality was 0.8% in both groups, and no difference was noted in the hospital stay (median 16 vs. 17 days). Five (3.9%) patients with synchronous CRC and three (2.4%) patients with solitary CRC developed anastomotic leakage. Prolonged surgery was correlated with high intra- and postoperative complications and 1.53–9.9 OR for developing anastomotic leakage [21]. However, the long-term outcomes showed a significant difference between the two

Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.



Fig. 1. (a) Kaplan–Meier curves of OS for synchronous CRC and solitary CRC patients. (b) Kaplan–Meier curves of DFS for synchronous CRC and solitary CRC patients. (c) Kaplan–Meier curves of CSS for synchronous CRC and solitary CRC patients. CRC, colorectal cancer; CSS, cancer-specific survival; DFS, disease-free survival; OS, overall survival.

TABLE 5. Multivariate analysis of clinicopathological parameters for the prediction of overall survival, disease-free survival, and cancer-specific survival

	OS			DFS			CSS		
Clinicopathological parameter	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Cancer grade (G), n (%)									
G1/G2	Reference			Reference			Reference		
G3/G4	3.336	1.907-5.835	< 0.001	2.434	1.488-3.984	< 0.001	2.879	1.574-5.267	0.001
Regional lymph node status (N),	n (%)								
NO	Reference			Reference			Reference		
N1/N2	4.231	2.264-7.907	< 0.001	3.778	2.209-6.460	< 0.001	2.854	1.418-5.747	0.003
CEA levels, ng/ml, n (%)									
<5	Reference			Reference			Reference		
≥5	1.912	1.095-3.340	0.023	1.659	1.012-2.720	0.045	2.017	1.122-3.624	0.019
Synchronous CRC, n (%)									
No	Reference			Reference			Reference		
Yes	2.355	1.322-4.195	0.004	2.079	1.261–3.429	0.004	2.429	1.313–4.493	0.005

CEA, carcinoembryonic antigen; CI, confidence interval; CRC, colorectal cancer; CSS, cancer-specific survival; DFS, disease-free survival; HR, hazard ratio; OS, overall survival.

groups. In multivariate analysis, synchronous CRC was an independent prognostic factor of OS (HR: 2.355, 95%) CI: 1.322–4.195, P = 0.004), DFS (HR: 2.079, 95% CI: 1.261-3.429, P = 0.004), and CSS (HR: 2.429, 95% CI: 1.313–4.493, P = 0.005). This difference might be caused by pathological characteristics. In the present study, MAC containing SC in synchronous CRC were more than in solitary CRC (50 vs. 27, OR: 2.412, 95% CI: 1.384-4.204). Another large cohort study demonstrated that MAC and SC were diagnosed at higher tumor stages and associated with a higher risk of tumor recurrence that in turn, reduced the rate of survival [22]. Moreover, the tumor deposit of synchronous CRC was significant in solitary CRC (25 vs. 13, OR: 2.152, 95% CI: 1.045-4.429). The data of SEER also indicated that tumor deposit and perineural invasion correlated independently with poor OS and CSS [23].

The prevalence of MSI-H and mismatch repair (MMR) protein-deficient tumors for synchronous CRC has been controversial. Hu *et al.* [10] reported that the MSI-H CRC accounts for approximately 35% of synchronous CRCs. Nakano *et al.* [24] stated that the frequency of MMR protein deficiency in synchronous CRC in the Japanese population may be lower as compared to that in the Western populations, and MMR protein loss and KRAS and BRAF mutations in synchronous CRCs were heterogeneous in the same patient. However, the prognostic relevance of MSI status of patients with synchronous CRC was yet unclear.

Nevertheless, the present study had some limitations. First, it was a single-center and retrospective design, which might weaken the statistical power of our findings. Additionally, the operation time was not matched accurately, necessitating a prolonged follow-up duration for solitary CRC than synchronous CRC, and hence, the selection bias could not be excluded.

#### Conclusion

Synchronous CRC is a unique subtype of colorectal cancer with marked disparity in clinical and pathological implications as compared to solitary CRC. The results of the present study showed a similar short-term outcome of synchronous CRC and solitary CRC patients in a matched pair analysis; however, patients with synchronous CRC exhibited worse OS, DFS, and CSS than those with solitary CRC.

#### Acknowledgements

We thank all the patients who participated in this study and provided the follow-up data. This work was supported by the Science and Technology Support Program of the Science and Technology Department of Sichuan Province (No. 2016SZ0043). This study was approved by the Ethics Committee of West China Hospital of Sichuan University, and the need to obtain informed consent was waived. Conceived and designed the experiments: Z.Q.W. and J.W. Data collection: W.B.H., M.T.W., and J.D. Analyzed the data: W.B.H., Y.H.W., and M.J.Z. Wrote the paper: W.B.H. and C.J.Z.

#### **Conflicts of interest**

There are no conflicts of interest.

# References

- 1 Gu J, Chen N. Current status of rectal cancer treatment in china. *Colorectal Dis* 2013; 15:1345–1350.
- 2 Jesinghaus M, Pfarr N, Kloor M, Endris V, Tavernar L, Muckenhuber A, et al. Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes Chromosomes Cancer 2016; 55:268–277.
- 3 Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. *World J Gastroenterol* 2014; 20:6815–6820.
- 4 Latournerie M, Jooste V, Cottet V, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous colorectal cancers. *Br J Surg* 2008; 95:1528–1533.
- 5 Lam AK, Carmichael R, Gertraud BP, Gopalan V, Ho YH, Siu S. Clinicopathological significance of synchronous carcinoma in colorectal cancer. *Am J Surg* 2011; 202:39–44.
- 6 Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between crohn's and ulcerative colitis based on three decades of experience. *Ann Surg* 2010; 252:330–335.
- 7 Liu X, Goldblum JR, Zhao Z, Landau M, Heald B, Pai R, Lin J. Distinct clinicohistologic features of inflammatory bowel disease-associated colorectal adenocarcinoma: in comparison with sporadic microsatellite-stable and lynch syndrome-related colorectal adenocarcinoma. *Am J Surg Pathol* 2012; 36:1228–1233.
- 8 Mohammadi M, Kristensen MH, Nielsen HJ, Bonde JH, Holck S. Qualities of sessile serrated adenoma/polyp/lesion and its borderline variant in the context of synchronous colorectal carcinoma. *J Clin Pathol* 2012; 65:924–927.
- 9 Leggett BA, Worthley DL. Synchronous colorectal cancer: not just bad luck? *Gastroenterology* 2009; 137:1559–1562.
- 10 Hu H, Chang DT, Nikiforova MN, Kuan SF, Pai RK. Clinicopathologic features of synchronous colorectal carcinoma: a distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. *Am J Surg Pathol* 2013; 37:1660–1670.
- 11 Oya M, Takahashi S, Okuyama T, Yamaguchi M, Ueda Y. Synchronous colorectal carcinoma: clinico-pathological features and prognosis. *Jpn J Clin Oncol* 2003; 33:38–43.
- 12 Yang J, Peng JY, Chen W. Synchronous colorectal cancers: a review of clinical features, diagnosis, treatment, and prognosis. *Dig Surg* 2011; 28:379–385.
- 13 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bmj* 2007; 335:806–808.
- 14 Edge SB, Compton CC. The American Joint Committee On Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010; 17:1471–1474.
- 15 van Leersum NJ, Aalbers AG, Snijders HS, Henneman D, Wouters MW, Tollenaar RA, Eddes EH. Synchronous colorectal carcinoma: a risk factor in colorectal cancer surgery. *Dis Colon Rectum* 2014; 57:460–466.
- 16 Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in asia. *Intest Res* 2016; 14:111–119.
- 17 Lu JY, Sheng JQ. Advances in the study of lynch syndrome in China. World J Gastroenterol 2015; 21:6861–6871.
- 18 Foster PA. Oestrogen and colorectal cancer: mechanisms and controversies. *Int J Colorectal Dis* 2013; 28:737–749.
- 19 Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383:1490-1502.
- 20 Triantafillidis JK, Vagianos C, Malgarinos G. Colonoscopy in colorectal cancer screening: current aspects. *Indian J Surg Oncol* 2015; 6:237–250.
- 21 van Rooijen SJ, Huisman D, Stuijvenberg M, Stens J, Roumen RMH, Daams F, Slooter GD. Intraoperative modifiable risk factors of colorectal anastomotic leakage: why surgeons and anesthesiologists should act together. *Int J Surg* 2016; 36:183–200.
- 22 Nitsche U, Friess H, Agha A, Angele M, Eckel R, Heitland W, et al. Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort. J Cancer Res Clin Oncol 2016; 142:2357–2366.
- 23 Mayo E, Llanos AA, Yi X, Duan SZ, Zhang L. Prognostic value of tumour deposit and perineural invasion status in colorectal cancer patients: a SEER-based population study. *Histopathology* 2016; 69:230–238.
- 24 Nakano K, Yamamoto H, Fujiwara M, Koga Y, Tsuruta S, Ihara E, et al. Clinicopathologic and molecular characteristics of synchronous colorectal carcinoma with mismatch repair deficiency. Am J Surg Pathol 2018; 42:172–182.